SCHEMBL2853482

SCHEMBL2853482

Cc1ccc(C(=O)NCC2(Cc3ccccc3)CCCCC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 5/20 0.51
POLB P06746 3/20 0.51
NPFFR1 Q9GZQ6 2/20 0.48
NPFFR2 Q9Y5X5 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPK14 Q16539 1/20 0.45
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
ADRB2 P07550 1/20 0.44
MAOA P21397 1/20 0.44
SLC6A9 P48067 1/20 0.43
SLC6A5 Q9Y345 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861616 0.91 LMNA (0.58) NPC1RAB9ALMNAPOLBNPFFR1
SCHEMBL5351381 0.81 ALDH1A1 (0.45) LMNAPOLBNPFFR1NPFFR2SMN1; SMN2
SCHEMBL2867565 0.81 NPC1 (0.57) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL9146667 0.79 OPRM1 (0.50) MEN1KMT2ANPC1RAB9ANPFFR1
SCHEMBL2856026 0.79 MEN1 (0.65) MEN1KMT2AALDH1A1
SCHEMBL5462309 0.79 TP53 (0.62) NPC1RAB9ALMNANPFFR1NPFFR2
SCHEMBL2857681 0.79 ALDH1A1 (0.67) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL14279001 0.78 CYP3A4 (0.41) MEN1KMT2ANPC1RAB9ANPFFR1
SCHEMBL2859748 0.77 GAA (0.48) LMNAPOLBSMN1; SMN2ALDH1A1MAOA
SCHEMBL2861400 0.77 NPC1 (0.53) NPC1RAB9ALMNANPFFR1NPFFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 MEN1 4430/4885KMT2A 1396/4885NPC1 675/4885
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 MEN1 4430/4885KMT2A 1396/4885NPC1 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.